focus trial semaglutide Efficacy and safety of once-weekly 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B Semaglutide results week by week:

This dual action reduces overall calorie intake and aids in weight loss

A next generation probiotic, Akkermansia muciniphila

This metabolic pathway creates a sustained release of L-arginine in your body

"This finding potentially opens the possibility of an entirely new pharmacological treatment paradigm, which could be used in conjunction with conventional methods, such as behavior therapy and group support." Potential limitations The study was limited by its relatively small number of patients, the researchers acknowledged

Semaglutide tends to produce a more gradual onset of side effects, allowing many patients to adapt as their bodies adjust to the medication

Maher, S